Holen Sie sich die Stockscreener-App
4.25
14.31%
-0.71
Vorhandelsmarkt:
4.12
-0.13
-3.06%
Cyclerion Therapeutics Inc Aktie (CYCN) Neueste Nachrichten
Cyclerion Therapeuticsinc Stock Price Forecast. Should You Buy CYCN? - StockInvest.us
Cyclerion Therapeutics Inc. (CYCN) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Cyclerion Therapeutics Inc. (CYCN) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Cyclerion Shareholders Approve Key Measures for Korsana Merger - TipRanks
Cyclerion TherapeuticsSets Sept 4, 2026 As Record Date For Cvr Distribution In Korsana MergerSEC Filing - TradingView
Cyclerion (NASDAQ: CYCN) sets CVR cutoff ahead of planned Korsana merger - Stock Titan
Balyasny Asset Management L.P. Initiates Position in Cyclerion T - GuruFocus
Cyclerion (NASDAQ: CYCN) CFO buys 25,000 shares in cash exercise - Stock Titan
Cyclerion (CYCN) CEO uses cashless exercise, forfeits 48,629 options - Stock Titan
Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership - Stock Titan
Cyclerion Therapeutics (CYCN): Balyasny group discloses 7.33% equity position - Stock Titan
Cyclerion (NASDAQ: CYCN) details Korsana merger plans and proxy materials - Stock Titan
Cyclerion Therapeutics (CYCN) outlines two-step merger structure with Korsana Biosciences - Stock Titan
Cyclerion Therapeutics (CYCN) outlines terms, risks and disclosures for proposed Korsana merger - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cyclerion FY26 Q2 net loss widens to $1.76 million; revenue falls to no revenue - Bitget
Cyclerion Therapeutics 2Q 2026: Revenue $0 Net loss $(1.76M) — 10-Q Summary - TradingView
Cyclerion Therapeutics (NASDAQ: CYCN) outlines Korsana merger and going concern risk - stocktitan.net
Cyclerion (CYCN) and Korsana add leaders as reverse merger targets Q3 2026 close - Stock Titan
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Cyclerion Therapeutics (CYCN) Holds Flat at $3.49 as Shares Trade Within Established RangeMid Cap Momentum - dars.gov.et
Cyclerion Therapeutics (CYCN) Slides to $3.44 as Clinical-Stage Biotech Holds Key Support ZoneGap Down Bounce Plays - vinanet.vn
Cyclerion Therapeutics (CYCN) Slips 1.7% to $3.44 as Consolidation ContinuesCall Flow Alert - vinanet.vn
CYCN Q4 2025 Earnings: Narrower-Than-Expected Loss Beats Estimates as Cost Discipline Takes Center Stage - vinanet.vn
Cyclerion Therapeutics (CYCN) Stock Slides Slightly as It Tests Key Support LevelTWAP Entry - vinanet.vn
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics (CYCN) Slides 3.31% as Stock Tests Key Support LevelsRVOL Breakout - po-news-eg.net
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics Inc (CYCN) Balance Sheet - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.370|Chg%:-0.130 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.440|Chg%:-0.060 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RKLBRocket Lab Stock Price Today, News, Analysis and Trading Ideas - Stocktwits
Cyclerion Therapeutics (CYCN) plans merger with Korsana and $380M financing - Stock Titan
Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com South Africa
Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion - Stock Titan
Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares - Stock Titan
Cyclerion Therapeutics Q4 2025 Earnings: Narrowing Losses Beat Expectations Amid Strategic Pipeline FocusFinancial Data - vinanet.vn
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Tightens Cost ControlProfit Recovery Report - dars.gov.et
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beat Driven by Disciplined Cost Management, Stock DeclinesManagement Tone Analysis - vinanet.vn
Cyclerion Therapeutics (CYCN) Retreats 1.9% as Stock Tests Crucial Support ZoneHidden Order - dars.gov.et
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal - Stock Titan
Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing - Stock Titan
Cyclerion Therapeutics (CYCN) Presses Lower: Support Test in FocusETF Creation Redemption - dars.gov.et
Cyclerion Therapeutics (CYCN) Gains 6.6% as Shares Test Key Resistance Near $3.55PCR Spike - dars.gov.et
Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Price to sales forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN) - TradingView
Cyclerion Therapeutics (CYCN) Faces Resistance as Shares Slide Nearly 4%Outside Reversal - dars.gov.et
Cyclerion Therapeutics (CYCN) Edges Higher as Stock Tests Key ResistanceIchimoku Cloud - dars.gov.et
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):